Evaluating a New MRI Scan to Measure Treatment Response in Patients With Colorectal Cancer That Has Spread to the Liver

What this Trial Is About

Researchers are studying colorectal cancer that has spread to the liver, focusing on how well a new MRI scan called intravoxel incoherent motion diffusion weighted imaging IVIM DWI can measure treatment response. The study aims to see if IVIM DWI can detect differences in disease changes before and after chemotherapy between patients who respond to treatment and those who do not. It also evaluates related imaging parameters and their correlation with tissue changes seen under the microscope after treatment. Participants undergo IVIM DWI scans during standard MRI sessions lasting about 10 minutes. These scans are performed within 30 days before starting chemotherapy and again after 4 to 6 cycles of preoperative chemotherapy, which may include oxaliplatin with fluorouracilleucovorin FOLFOX, irinotecan with 5-FUleucovorin FOLFIRI, or a combination such as FOLFOXIRI, with or without biologic agents. The imaging is used to study changes in diffusion parameters and treatment effects. Throughout the study, participants receive routine MRI scans combined with IVIM DWI before and after chemotherapy to monitor treatment effects. Researchers measure changes in the true diffusion coefficient and other diffusion-related parameters up to 3 to 5 months depending on chemotherapy cycles. The study includes assessments before surgery and during follow-up at the cancer center to evaluate the disease response using imaging and pathology results.

An Investigational Scan (Intravoxel Incoherent Motion Diffusion Weighted Imaging) for the Evaluation of Colorectal Cancer Liver Metastases Treatment Response